Study wrapper · #903
Effect of semaglutide on hidradenitis suppurativa disease control and quality of life: A case series.
Drayne R, Lyons D, Kirby B, et al. Journal of the European Academy of Dermatology and Venereology : JEADV. 2026.
DOI: 10.1111/jdv.70614PubMed: 42466886
Editor's note
Semaglutide is the direct subject here, studied for its association with hidradenitis suppurativa outcomes. As an uncontrolled case series with no abstract detail available, the evidence is weak and hypothesis-generating. Worth noting as an emerging off-label signal, but not a basis for firm conclusions.
Plain-language abstract
This case series reports on semaglutide use in patients with hidradenitis suppurativa, describing changes in disease control and quality of life.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026